SELECTION OF A SMALL MOLECULE TAU OLIGOMER INHIBITOR FOR IND ENABLING STUDIES
Selection Of A Small Molecule Tau Oligomer Inhibitor For Ind Enabling Studies

SELECTION OF A SMALL MOLECULE TAU OLIGOMER INHIBITOR FOR IND ENABLING STUDIES

Chicago October 22, 2019 Time: 10:00 am – 10:15 am McCormick Place, Room S103 Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, will present preclinical data on its lead product candidate at Neuroscience 2019, the 49th annual conference of the Society for Neuroscience, being held in Chicago from October 19-23. In an oral presentation, James Moe, Ph.D., MBA, President and CEO of Oligomerix® will discuss the results of in vitro and in vivo studies with its small molecule tau inhibitor. There is a critical unmet need for disease-modifying drugs for AD and related dementias, and the role tau plays in the disease has become an important target for drug discovery and development. Oligomerix and other research labs have shown that tau oligomers are directly neurotoxic, inhibit signal transmission between neurons, and impair formation of memory in mice. Oligomerix’s core technology is focused on developing small molecule inhibitors of tau self-association, the initial step in the formation of pathological tau oligomers at the beginning of the tau aggregation cascade. Oligomerix’s lead compound has demonstrated efficacy in preclinical studies, and preclinical safety studies are in progress. A complementary mechanistic biomarker is being developed to facilitate clinical development.